Sugi Predict

Sugi Predict / Compounds / SCHEMBL1949138

SCHEMBL1949138

SCHEMBL1949138

CC(C)(C)OC(=O)NOC(=O)C(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DGAT1 O75907 1/20 0.41
▸ CA1 P00915 3/20 0.40
▸ CA2 P00918 3/20 0.40
▸ CA12 O43570 3/20 0.40
▸ CA9 Q16790 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.37
▸ CA7 P43166 2/20 0.36
▸ MAOA P21397 1/20 0.36
▸ MAOB P27338 1/20 0.36
▸ MEN1 O00255 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ MIF P14174 1/20 0.35
▸ CA14 Q9ULX7 2/20 0.34
▸ APLNR P35414 1/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ RECQL P46063 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ CTSK P43235 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28101880 0.83 DGAT1 (0.39) DGAT1CA1CA2CA12CA9
SCHEMBL28026126 0.81 CA12 (0.41) DGAT1CA1CA2CA12CA9
SCHEMBL29422137 0.81 CA12 (0.41) DGAT1CA1CA2CA12CA9
Trifluoromethanesulfonic Acid SCHEMBL29728758 0.80 CA12 (0.36) CA1CA2CA12CA9TDP1
SCHEMBL3954811 0.79 CA1 (0.38) DGAT1CA1CA2CA12CA9
SCHEMBL1609396 0.79 CA12 (0.41) DGAT1CA1CA2CA12CA9
SCHEMBL874509 0.79 CA12 (0.41) DGAT1CA1CA2CA12CA9
SCHEMBL20711946 0.79 CA1 (0.41) DGAT1CA1CA2CA12CA9
SCHEMBL3346353 0.79 CA12 (0.41) DGAT1CA1CA2CA12CA9
SCHEMBL24191656 0.78 DGAT1 (0.41) DGAT1CA1CA2CA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4192454-B1 AZABICYCLO-AMINO-TRIAZINE COMPOUNDS FOR MODULATING SPLICING FOR THE TREATMENT OF NEUROLOGICAL DISEASES SKYHAWK THERAPEUTICS INC (US) 2026-04-22 — — EP disclosed
CN-121064056-A Synthetic method of N-deuterated methyl aromatic amine and derivative thereof 南开大学 2025-12-05 — — CN disclosed
US-12454534-B2 Pyrrolo[2,3-b]pyrazines as HPK1 inhibitor and the use thereof BEONE MEDICINES I GMBH (CH) 2025-10-28 — — US disclosed
US-20250084074-A1 SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS MERCK PATENT GMBH (DE) 2025-03-13 — — US disclosed
EP-4463444-A1 SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS Merck Patent GmbH (DE) 2024-11-20 — — EP disclosed
CN-118043324-A Pyrrolo [2,3-b ] pyrazine-based bifunctional compounds as HPK1 degradants and uses thereof 百济神州有限公司 2024-05-14 — — CN disclosed
US-20240116856-A1 NOVEL CAPSAICIN ANALOGS AND USES THEREOF YOUNG BIOPHARMA, LLC 2024-04-11 — — US disclosed
US-20230331718-A1 COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-10-19 — — US disclosed
US-20230331718-A1 COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-10-19 — — US disclosed
WO-2023131690-A1 SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS MERCK PATENT GMBH (DE) 2023-07-13 — — WO disclosed
US-9018411-B2 Bis-acylated hydroxylamine derivatives CARDIOXYL PHARMACEUTICALS, INC. (US) 2015-04-28 — — US disclosed
US-8987504-B2 Aminohydroxylation of alkenes VICTORIA LINK LIMITED (NZ) 2015-03-24 — — US disclosed
US-20140235636-A1 N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES CARDIOXYL PHARMACEUTICALS, INC. (US) 2014-08-21 — — US disclosed
US-20130274479-A1 AMINOHYDROXYLATION OF ALKENES INDUSTRIAL RESEARCH LIMITED (NZ) 2013-10-17 — — US disclosed
EP-2509942-A2 BIS-ACYLATED HYDROXYLAMINE DERIVATIVES Johns Hopkins University (US) 2012-10-17 — — EP disclosed
WO-2011159177-A1 IMPROVED AMINOHYDROXYLATION OF ALKENES INDUSTRIAL RESEARCH LIMITED (NZ) 2011-12-22 — — WO disclosed
CN-102264721-A Compounds useful as inhibitors of ATR kinase — 2011-11-30 — — CN disclosed
WO-2011071947-A2 BIS-ACYLATED HYDROXYLAMINE DERIVATIVES JOHNS HOPKINS UNIVERSITY (US) 2011-06-16 — — WO disclosed
US-20110144067-A1 N-Acyloxysulfonamide and N-Hydroxy-N-Acylsulfonamide Derivatives THE JOHNS HOPKINS UNIVERSITY 2011-06-16 — — US disclosed
US-20110136827-A1 Bis-Acylated Hydroxylamine Derivatives THE JOHNS HOPKINS UNIVERSITY 2011-06-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230331718-A1 COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SNRPE DGAT1 1915/4885CA1 4860/4885CA2 4870/4885
US-20140235636-A1 N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES TNNI3, TNNT2, TNNC1 DGAT1 705/4885CA1 1354/4885CA2 425/4885
US-20130274479-A1 AMINOHYDROXYLATION OF ALKENES ALKBH3, ALKBH1, ALKBH2 DGAT1 1122/4885CA1 633/4885CA2 551/4885
US-20240116856-A1 NOVEL CAPSAICIN ANALOGS AND USES THEREOF NPY5R, GPR119, NPY4R DGAT1 1653/4885CA1 2248/4885CA2 816/4885
US-20250084074-A1 SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS VHL, CDKN1A, CCNI DGAT1 2150/4885CA1 4779/4885CA2 4377/4885
US-12454534-B2 Pyrrolo[2,3-b]pyrazines as HPK1 inhibitor and the use thereof PDXK, STK25, STK35 DGAT1 4266/4885CA1 4401/4885CA2 3455/4885
US-20110144067-A1 N-Acyloxysulfonamide and N-Hydroxy-N-Acylsulfonamide Derivatives TNNI3, TNNT2, TNNC1 DGAT1 705/4885CA1 1354/4885CA2 425/4885
US-20110136827-A1 Bis-Acylated Hydroxylamine Derivatives CPT1A, TNNI3, NOS2 DGAT1 417/4885CA1 1379/4885CA2 627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.